Work

Exploring considerations for the development of conceptual frameworks to support clinical outcome assessments used in medical product development

Year: 2026
Type: article
Study design: Observational Study
Abstract: Background The Food and Drug Administration (FDA) Patient-Focused Drug Development (PFDD) Draft and Final Guidance 3 provide depictions of conceptual frameworks incorporating conceptual and measurement models for all clinical outcome assessment (COA) types; however, operational guidance for framework development is limited. Members of the International Society for Quality of Life Research (ISOQOL) Industry Special Interest Group (I-SIG) investigated current practices and perspectives to identify and disseminate key considerations for the development of conceptual frameworks to support COAs for regulatory submissions. Methodology Using an online survey of I-SIG members, the authors investigated current perspectives and practices addressing four key conceptual framework development topics: use of theoretical health/disease experience models/frameworks; conceptual model comprehensiveness; selection of COA type(s); and effective collaboration for conceptual model development. Results From 24 I-SIG survey respondents, several key considerations emerged (≥67% respondent agreement). Most respondents endorsed using published theoretical models/frameworks of health and/or behavior to support the development of conceptual models or COA strategies for clinical trials ( n = 19/24; 79%). These published models/frameworks were used to identify concepts of interest (COIs) that may be used to develop a measurement model using a COA and/or other strategy ( n = 16/19; 84%), and most respondents ( n = 18/22; 82%) recommended using a published model/framework in regulatory submissions. The majority of respondents disagreed that conceptual models should include only concepts reported “spontaneously” ( n = 19/24; 79%). Respondents determined which COI(s) warrants development of a measurement model based on each COI’s relevance to patients ( n = 16/20; 80%). The type of COA selected for evaluation of a COI depends upon the assessed COI ( n = 22/22; 100%), whether the COI is observable ( n = 21/22; 95%), characteristics of the target population ( n = 20/22; 91%), availability of existing measures ( n = 15/22; 68%), and if inclusion of more than one COA for the same COI is warranted ( n = 16/19; 84%). Finally, respondents advocated for effective conceptual model development that incorporates patient stakeholders ( n = 17/17; 100%), each with a role and commitment to capture the patient experience through their unique perspective, and healthcare professionals who regularly interact with patients ( n = 15/17; 88%). Conclusion This investigation’s guidance-generating considerations provide practical insights for developing conceptual frameworks used in medical product development.
Language: English
Open Access status: gold
Estimated APC paid: $1,990
OpenAlex ID: W7235206617
FWCI:
Cites:
Cited by:
Related to: 10